Zydus Lifesciences gets EIR from USFDA for Jarod facility

The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs.

Published On 2022-05-28 06:03 GMT   |   Update On 2022-05-28 06:04 GMT

Ahmedabad: Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), a global lifesciences company has announced that the company has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Jarod injectables manufacturing facility near Vadodara, India. Establishment Inspection Report means the closure of inspection.

The USFDA had inspected the facility from 24th February to 10th March, 2022.

Zydus said that the USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI) and has concluded that the inspection is considered as "closed" under 21 CFR 20.64(d)(3). The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs.

Voluntary Action Indicated (VAI) means objectionable conditions or practices that were found but the agency is not prepared to take or recommend any administrative or regulatory action.

Read also: Zydus Lifesciences Chemotherapy drug Pemetrexed gets USFDA okay

Medical Dialogues team had earlier reported that Zydus Lifesciences had received three observations from the US health regulator after inspection of its Jarod (Vadodara) based manufacturing facility.

Read also: USFDA issues 3 observations for Zydus Lifesciences's Vadodara plant

Zydus group is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News